Aperio Group LLC grew its position in shares of Mednax, Inc (NYSE:MD) by 76.1% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 41,688 shares of the company’s stock after buying an additional 18,012 shares during the quarter. Aperio Group LLC’s holdings in Mednax were worth $1,798,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently made changes to their positions in MD. Pacer Advisors Inc. grew its stake in shares of Mednax by 8.1% during the 2nd quarter. Pacer Advisors Inc. now owns 1,940 shares of the company’s stock worth $117,000 after purchasing an additional 145 shares during the period. Commonwealth Bank of Australia grew its stake in shares of Mednax by 15.3% during the 2nd quarter. Commonwealth Bank of Australia now owns 2,205 shares of the company’s stock worth $132,000 after purchasing an additional 293 shares during the period. Daiwa Securities Group Inc. grew its stake in shares of Mednax by 20.0% during the 2nd quarter. Daiwa Securities Group Inc. now owns 3,000 shares of the company’s stock worth $181,000 after purchasing an additional 500 shares during the period. Denali Advisors LLC acquired a new position in shares of Mednax during the 3rd quarter worth $185,000. Finally, Meiji Yasuda Asset Management Co Ltd. acquired a new position in shares of Mednax during the 2nd quarter worth $217,000. Institutional investors own 96.28% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Aperio Group LLC Has $1.80 Million Holdings in Mednax, Inc (MD)” was posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://transcriptdaily.com/2017/11/15/aperio-group-llc-has-1-80-million-holdings-in-mednax-inc-md.html.
In other Mednax news, Director Cesar L. Alvarez sold 10,668 shares of the company’s stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $42.59, for a total value of $454,350.12. Following the transaction, the director now directly owns 44,215 shares in the company, valued at approximately $1,883,116.85. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider John C. Pepia sold 3,000 shares of the company’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $42.85, for a total transaction of $128,550.00. Following the completion of the transaction, the insider now owns 35,569 shares in the company, valued at $1,524,131.65. The disclosure for this sale can be found here. 2.40% of the stock is currently owned by corporate insiders.
Shares of Mednax, Inc (NYSE:MD) opened at $46.32 on Wednesday. The company has a market cap of $4,253.82, a PE ratio of 13.89, a P/E/G ratio of 1.46 and a beta of 0.32. Mednax, Inc has a 12 month low of $40.56 and a 12 month high of $72.13. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 0.62.
Mednax (NYSE:MD) last issued its quarterly earnings data on Wednesday, November 1st. The company reported $0.87 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.87. The firm had revenue of $868.95 million for the quarter, compared to analysts’ expectations of $864.78 million. Mednax had a net margin of 7.76% and a return on equity of 10.80%. The firm’s revenue was up 4.9% on a year-over-year basis. During the same period in the prior year, the company earned $1.09 EPS. equities analysts anticipate that Mednax, Inc will post 3.1 earnings per share for the current year.
A number of research firms have recently weighed in on MD. Citigroup Inc. lowered their price target on shares of Mednax from $52.00 to $47.00 and set a “neutral” rating on the stock in a research note on Friday, November 3rd. Robert W. Baird upped their price target on shares of Mednax from $47.00 to $48.00 and gave the stock a “neutral” rating in a research note on Friday, November 3rd. Jefferies Group LLC reaffirmed a “hold” rating and set a $44.00 price target on shares of Mednax in a research note on Friday, November 3rd. KeyCorp set a $51.00 price target on shares of Mednax and gave the stock a “buy” rating in a research note on Wednesday, November 1st. Finally, BMO Capital Markets began coverage on shares of Mednax in a research note on Monday, October 16th. They set a “market perform” rating and a $46.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and two have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $54.50.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.